Novo Nordisk has appointed Edward L. Williams vice president of biopharmaceuticals and a member of the executive team. In this position, Mr. Williams will build and execute the business strategies for the biopharmaceuticals business unit and will set direction for the company’s biopharmaceutical products, including hemostasis, growth hormone therapy, and hormone therapy for women. Mr. Williams brings 26 years of industry experience to Novo Nordisk. Most recently, he served as vice pre...